Business Wire

OR-RADISYS

17.12.2020 14:02:14 CET | Business Wire | Press release

Share
ContactMakers Selects Radisys Engage Media Server to Power Cloud-Based Customer Interaction Suite

Radisys® Corporation , a global leader of open telecom solutions, today announced that ContactMakers , a contact center telephony solutions and customer care provider, has selected Radisys Engage Media Server as the foundation for its VOIP Communication ContactSuite platform as it moves the solution to the cloud. The Engage Media Server’s extensive flexible capabilities enable ContactMakers to focus its resources to add unique applications, enhanced user experience and custom capabilities for its unique customer interaction suite, rather than on the communications infrastructure. ContactMakers will be able to use the media server to address specific customer requirements more quickly, while reducing costs and complexity by utilizing a common media processing platform for advanced voice, video, media analytics, and other capabilities for its customer offerings.

Highlights

  • Customer contact is always critical to business. Despite the evolution and expansion of communication channels including the internet, text messaging and social media, telecommunications access solutions like business VOIP, mobile and landlines continue to anchor a high volume of interactions including the most critical customer care interactions.
  • With today’s fluid workforce, dynamic global conditions and a growing trend toward remote customer interactions, having a reliable media foundation for real-time voice and video sessions is more critical than ever. To meet this challenge, businesses need a contact center solution that enables them to bring new, scalable and elastic services online more quickly and that can be adapted to changing market conditions more easily than existing off-the-shelf Customer Communication-as-a-Service (CCaaS) products.
  • ContactMakers is undertaking a telco-to-the-cloud migration of its proprietary communications application and interaction platform which it has built and optimized for clients’ customer communication requirements for more than 15 years. Leveraging Radisys Engage Media Server’s cloud-native platform, ContactMakers will be able to lower the cost of migration, deliver greater flexibility, and provide optimal resource utilization.
  • ContactMakers will use the Engage Media Server to deliver telco-grade reliability, video, speech processing, biometrics, and high-quality voice capabilities as the anchor for its service platform.
  • Radisys Engage Media Server is the industry’s leading real-time media processing platform that provides voice, video, and AI-based media, delivering a complete solution set for developers, CCaaS providers and Communications Service Providers (CSP) to create a wholistic digital customer engagement experience.
  • Customer Care, Unified Communications (UC) and CCaaS providers, including OEM and managed service providers alike, depend on Radisys for high quality, cloud-based media processing that can meet dynamic customer, market, and employee conditions, while providing a future-proof, market leading solutions including:
    • Cloud scalability for broader market reach for digital experience applications and services at attractive price points
    • Highest quality voice and video processing
    • Support for VOIP, mobile and landline customer and employee connections
    • Telco-grade reliability to ensure “always on” communications

“We have had a long relationship with Radisys to deliver high-quality communication services that our customers expect. Now, with Radisys’ help, we are able to seamlessly transition to a software environment that can run in our private data center or in the cloud,” said Denise Konings, CEO, ContactMakers. “The combination of Radisys technology, its consultative expertise in the rapidly evolving communications and mobile technology domain, and its world-class global support make Radisys not only a technology supplier, but our key partner in delivering high quality, engaging, customer interactions.”

“Reliable, scalable and cloud-based media processing is the foundation for delivering memorable customer interactions,” said Shankar Krishnamurthy, Radisys’ Senior Director, Business Development. “Engage Media Server is enabling ContactMakers to migrate its services to the cloud to better manage communication workflows, improve the user experience, and track critical customer and employee key performance indicators. It also allows ContactMakers to continue to focus its specialized resources and development budget on service applications.”

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com .

About ContactMakers

ContactMakers facilitates and realizes top-level telephony for companies that go for quality in customer service. Superior communication technology in the cloud combined with people skills, passion and drive. ContactMakers inspires and challenges you to make every customer contact moment the best that it can be. Together we'll optimize every phase of the customer experience cycle. Visit www.contactmakers.nl for more information.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye